Chen Z, Lian F, Wang X, Chen Y, Tang N. Int J Nanomedicine. 2016;11:4247–4259.
The authors have advised Figure 5D on page 4256 is incorrect. Due to an error that occurred inadvertently at the time of figure assembly, the β-Actin row in parts C and D were duplicated. The correct Figure 5 is shown below.
Figure 5.
Continued.
Figure 5.
Effects of RGD-PEG-PAMAM on the synthesis of albumin and urea in Huh7 cells.
Notes: (A) Albumin level in the supernatant of different cells in cultivation for 1, 3, and 5 days. Group data represent mean ± standard deviation (n=3). *P<0.05 (n=3), **P<0.01 (n=3) compared to Huh7 cells treated with nothing (control). (B) Comparison of urea production. Data represent mean ± standard deviation (n=3) of urea production. *P<0.05 (n=3) compared to Huh7 cells treated with nothing or PEG-PAMAM. (C) Representative immunoblots from three independent studies for Arg1, OTC, and β-actin in Huh7 cells treated with 100 μg/mL RGD-PEG-PAMAM for 1, 3, and 5 days. The densitometry data were normalized to β-actin. *P<0.05 (n=3), **P<0.01 (n=3) compared to treatment for 1 or 5 days. (D) Representative immunoblots from three independent studies for Arg1, OTC, and β-actin in Huh7 cells treated with 100 μg/mL RGD-PEG-PAMAM, PEG-PAMAM, or nothing for 3 days. The densitometry data were normalized to β-actin. *P<0.05 (n=3), **P<0.01 (n=3) compared to treatment with PEG-PAMAM or nothing.
Abbreviations: RGD, arginine–glycine–aspartic acid; PEG, polyethylene glycol; PAMAM, polyamidoamine.
The authors apologize for the error and advise it does not affect the results and conclusions of the paper.